August 21, 2024
Tokyo Medical and Dental University
Celaid Therapeutics Inc.

Tokyo Medical and Dental University and Celaid Therapeutics Inc.
Joint Research Agreement on Research and Development of Gene-modified Cell
Therapy Using Human Bone Marrow Hematopoietic Stem Cells (HSCs)
Tokyo Medical and Dental University (TMDU) and Celaid Therapeutics Inc. (Celaid) are pleased toannounce the signing of a joint research agreement.
This agreement was established for research and development of novel gene-modified cell therapies
using human bone marrow HSCs for inborn errors of immunity* and is expected to spur nextgeneration gene-modified cell therapy development in Japan. Distinguished Research Professor
Tomohiro Morio with his team at the TMDU Laboratory of Immunology and Molecular Medicine andCelaid will jointly explore new treatments for inherited immune disorders through the application ofCelaid’s novel HSC expansion technology to HSCs isolated from human bone marrow. These cells
will be evaluated after gene modification.
In pursuing this project, TMDU and Celaid will be advancing the research and development of genetherapies using human HSCs based on domestically produced technology and research results, andwe will strive to accelerate the delivery of treatments to patients suffering from inborn errors ofimmunity.
* This project, "Research and Development of Novel Gene-modified Cell Therapies for inborn errorsof immunity" at TMDU is commissioned by the Japan Agency for Medical Research and Development(AMED) as a part of the AMED program for R&D Program of Regenerative Medicine and Cell andGene Therapy from the Basic to Nonclinical Phase in the Acceleration Program of R&D andimplementation for Regenerative Medicine and Cell and Gene Therapy.
Overview of Tokyo Medical and Dental University
Tokyo Medical and Dental University was established as a national educational institution for dentistryon October 12, 1928, and currently located in the Yushima/Shoheizaka area of Tokyo, which isconsidered sacred ground for scholarship and learning in Japan. Since then, as Japan’s only
comprehensive medical university and graduate school, TMDU has provided advanced medical
treatment through a fusion of the medical and dental fields and worked to cultivate “professionals withknowledge and humanity,” thereby contributing to human health and the well-being of society.
Institute of Science Tokyo (Science Tokyo) was established on October 1, 2024, following the merger
between Tokyo Medical and Dental University (TMDU) and Tokyo Institute of Technology (Tokyo Tech),with the mission of “Advancing science and human wellbeing to create value for and with society.

Celaid Therapeutics Overview
Celaid Therapeutics Inc. is a startup born out of the University of Tokyo and University of Tsukuba
with proprietary technology for selective ex vivo HSC expansion. By safely and efficiently expanding
human HSCs, Celaid aims to provide the next generation of cell and gene therapy products for celltherapy targeting hematologic disease, ex vivo HSC gene therapy for genetic disorders, andangiogenesis for ischemic diseases.

Contact Information
Tokyo Medical and Dental University
Public Relations Unit, General Coordination and Secretarial Section, General Affairs Division.
TEL: +81-3-5803-5833 FAX: 03-5803-0272
E-mail: kouhou.adm@tmd.ac.jp
URL: https://www.tmd.ac.jp/
Celaid Therapeutics Inc.
Address: Utokyo Entrepreneur Lab
South Clinical Research Bldg.
7-3-1 Hongo,Bunkyo-ku, Tokyo 113-8485, Japan
TEL: +81-50-3612-7767／E-mail: contact@celaidtx.com
URL: https://celaidtx.com/en/